These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
356 related items for PubMed ID: 28092996
41. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Sawyer JR. Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186 [Abstract] [Full Text] [Related]
42. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Chang H, Ning Y, Qi X, Yeung J, Xu W. Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306 [Abstract] [Full Text] [Related]
45. [The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma]. Guo R, Shen XX, Xia Y, Jin YY, Li JY, Chen LJ, Qiu HR. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):768-773. PubMed ID: 38926965 [Abstract] [Full Text] [Related]
46. [Detection of chromosomal aberrations in multiple myeloma with fluorescence in situ hybridization]. Cao P, Chen F, Cheng Y. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 37(10):983-9. PubMed ID: 23117450 [Abstract] [Full Text] [Related]
49. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, Mansoor A, Chen C, Masih-Khan E, Trieu Y, Bruyere H, Stewart DA, Bahlis NJ. Blood; 2009 Jul 16; 114(3):522-5. PubMed ID: 19332768 [Abstract] [Full Text] [Related]
53. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. An G, Xu Y, Shi L, Zou D, Deng S, Sui W, Xie Z, Hao M, Chang H, Qiu L. Leuk Res; 2013 Oct 16; 37(10):1251-7. PubMed ID: 23927993 [Abstract] [Full Text] [Related]
57. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China. Lai YY, Huang XJ, Cai Z, Cao XS, Chen FP, Chen XQ, Chen BA, Fang MY, Feng JF, Fu WL, Guo HY, Hou M, Hou J, Hu Y, Hu XT, Hu XM, Huang LQ, Jin J, Li JY, Li J, Li W, Liang YM, Liu T, Liu QF, Liu YH, Mao P, Ouyang J, Qiu LG, Qiu L, Shao CK, Shi B, Song YP, Sun ZM, Wang QS, Wang C, Wang JM, Wang YS, Wang Z, Wu JB, Wu YX, Xia RX, Xue YQ, Yang BZ, Yang G, Yang ZL, Yu L, Yuan Z, Zhang S, Zhang Y, Zhao HG, Zhao L, Zhou DB, Zou SH, Zhu YF. Chin Med J (Engl); 2012 Aug 16; 125(15):2663-70. PubMed ID: 22931972 [Abstract] [Full Text] [Related]
58. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Biol Blood Marrow Transplant; 2013 Aug 16; 19(8):1227-32. PubMed ID: 23733001 [Abstract] [Full Text] [Related]
59. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India. Kadam Amare PS, Jain H, Nikalje S, Sengar M, Menon H, Inamdar N, Subramanian PG, Gujral S, Shet T, Epari S, Nair R. Indian J Med Res; 2016 Oct 16; 144(4):536-543. PubMed ID: 28256461 [Abstract] [Full Text] [Related]